Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
Actinium presented first-in-human Phase 1 data for ATNM-400, its HER3-targeted Actinium-225 radiotherapy in mCRPC, in an oral presentation at EANM 2026. The initial three-patient cohort cleared the 1.0 µCi/kg dose level with no dose-limiting toxicities, xerostomia, or Grade 3/4 hematologic adverse events, and HER3-targeted PET imaging showed tumor uptake and retention through Day 7.
Key figures
- Drug Name
- ATNM-400 (barecetamab + Actinium-225)
- Phase Of Trial
- Phase 1
- First dose level
- 1.0 µCi/kg
- Second dose level
- 1.5 µCi/kg
- Planned dose levels
- ["1.0","1.5","2.25","3.0 µCi/kg"]
- Dose limiting toxicities
- 0
- Patients dosed first cohort
- 3
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.